$BDSI News
Last published 4y ago
- 4y agoGNTABDSIGenenta Provides First Half 2022 Business Update and Financial ResultsGlobeNewswireCurrent dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30,
- 4y agoBDSIGNTAGenenta Announces Nomination of Mark A. Sirgo as ChairGlobeNewswire35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnolo
- 4y agoBDSICOLLCollegium Completes the Acquisition of BDSIGlobeNewswireSTOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisitio
- 4y agoBDSIBioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of MigraineGlobeNewswireThe First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -
- 4y agoBDSIEYESGIIXZWSMoore Kuehn Encourages BDSI, ZWS, EYES, and GIIX Investors to Contact Law FirmPR NewswireNEW YORK, Feb. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 4y agoBDSIBDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences International to Collegium PharmaceuticalGlobeNewswireMONSEY, N.Y., Feb. 14, 2022 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether the directors of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) ("BDSI") acted in the best interests of BDSI shareholders in approving
- 4y agoBDSICOLLCollegium to Acquire BioDelivery Sciences in an All-Cash DealGlobeNewswireTransaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock's closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $
- 4y agoBDSICOLLCollegium to Acquire BioDelivery Sciences Broadening Pain PortfolioGlobeNewswire- Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA® Provides a Second Growth Driver and ELY
- 4y agoBDSIBioDelivery Sciences Expects 2021 Revenue at the High End of Full Year GuidanceGlobeNewswireTotal 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million
- 4y agoBDSIBioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032GlobeNewswireRALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S.
- 5y agoBDSIBioDelivery Sciences Reports Solid Third Quarter 2021 ResultsGlobeNewswireTotal Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral s
- 5y agoBDSIBioDelivery Sciences International, inc (BDSI) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsBDSI earnings call for the period ending October 31, 2021.
- 5y agoBDSIBioDelivery Sciences Appoints John Golubieski as Chief Financial OfficerGlobeNewswireRALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appo
- 5y agoBDSIBioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021GlobeNewswireRALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quar
- 5y agoBDSIBioDelivery Sciences International to Host ELYXYB™ Investor DayGlobeNewswireThe First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Virtual Event on October 14, 2021 RALEIGH, N.C., Sept. 30, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International,
- 5y agoBDSIBioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and CanadaGlobeNewswireExpands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022
- 5y agoBDSIBioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 ConferenceGlobeNewswireRALEIGH, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding
- 5y agoBDSIBioDelivery Sciences to Participate in Upcoming Virtual Investor ConferencesGlobeNewswireRALEIGH, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that
- 5y agoBDSIBioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of MigraineGlobeNewswireThe only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036 RALEIGH, N.C., Aug. 04, 2021 (GLOBE NEWSWIR
- 5y agoBDSIBioDelivery Sciences International, inc (BDSI) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsBDSI earnings call for the period ending June 30, 2021.
- 5y agoBDSIBioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021GlobeNewswireRALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that i
- 5y agoBDSIBioDelivery Sciences Reports First Quarter 2021 ResultsGlobeNewswireTotal Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 MillionConference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C., May
- 5y agoBDSIBioDelivery Sciences International, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 8:30 AM Eastern Time. To listen to the even
- 5y agoBDSIBiodelivery Sciences International Inc (BDSI) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsBDSI earnings call for the period ending March 31, 2021.
- 5y agoBDSIBioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021GlobeNewswireRALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that
- 5y agoBDSIBiodelivery Sciences International Inc (BDSI) Q4 2020 Earnings Call TranscriptEarnings Call TranscriptsBDSI earnings call for the period ending December 31, 2020.
- 5y agoBDSIBioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 ResultsGlobeNewswireTotal Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million, Full-Year EBITDA Margin of 26% and...
- 5y agoBDSIBioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021GlobeNewswireRALEIGH, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 5y agoBDSIBioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice PresidentGlobeNewswireRALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
- 5y agoMRNABDSIVRTXTRILAn Aging Population is Increasing the Need for Novel TreatmentsPR NewswireWith the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population...
- 5y agoBDSIBioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) MeetingGlobeNewswireOral Presentation of Data from Phase I Safety Study & Secondary Respiratory OutcomesComparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C., Jan. 15, 2021 (GLOBE...
- 5y agoBDSIBioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare ConferenceGlobeNewswireRALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 5y agoBDSINew patent application published for: Multidirectional Mucosal Delivery Devices and Methods of UseUS Patent Applications (USPTO)
- 6y agoBDSIBioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18GlobeNewswireRALEIGH, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 6y agoBDSIBioDelivery Sciences International, Inc. (BDSI) CEO Jeff Bailey on Q3 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoBDSIBioDelivery Sciences Reports Strong Q3 2020 ResultsGlobeNewswireTotal Company Net Revenue Increased 30% versus Prior Year Reaching a Record $39.4 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE)...
- 6y agoBDSIBioDelivery Sciences Announces $25 Million Share Repurchase ProgramGlobeNewswireRALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 6y agoBDSIBioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEOGlobeNewswireRALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 6y agoBDSIBioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020GlobeNewswireRALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 6y agoBDSIBioDelivery Sciences Announces Five Scientific Poster Presentations at PAINWeek® 2020 National Conference on Pain ManagementGlobeNewswireRALEIGH, N.C., Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
- 6y agoBDSIBioDelivery Sciences to Present at Two Upcoming Investor ConferencesGlobeNewswireRALEIGH, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
- 6y agoBDSIBioDelivery Sciences International, Inc. (BDSI) Management on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoBDSIBioDelivery Sciences Reports Strong Q2 2020 ResultsGlobeNewswireSecond Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic®...
- 6y agoBDSIBioDelivery Sciences to Report Second Quarter 2020 Financial Results on August 5, 2020GlobeNewswireRALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 6y agoBDSIBioDelivery Sciences to Present at Two Upcoming Investor ConferencesGlobeNewswireRALEIGH, N.C., May 29, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 6y agoBDSIBioDelivery Sciences Appoints Jeff Bailey Interim CEOGlobeNewswireRALEIGH, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...
- 6y agoBDSIBioDelivery Sciences Reports Strong Q1 2020 ResultsGlobeNewswireFirst Quarter Total Company Net Sales Increased 94% versus Prior Year to $38.3 Million First Quarter BELBUCA® Net Sales Increased 79% versus Prior Year to $33.5 Million Conference Call and...
- 6y agoINNTBDSI9 Meters Biopharma, a Rare, Orphan and Unmet Needs GI-Focused Company, is Created with the Transformative Merger Between Innovate Biopharmaceuticals and RDD PharmaACCESS NewswireCompletes concurrent financing of ~$22 million led by Orbimed Advisors, LLC
- 6y agoBDSIBioDelivery Sciences Reports Strong Fourth Quarter and Full-Year 2019 ResultsGlobeNewswireFull-Year Total Company Net Sales Increased 100% versus Prior Year to $111.4 Million Full-Year BELBUCA® Net Sales Increased 112% versus Prior Year to $97.5 Million Fourth Quarter Total Company Net...
- 6y agoBDSIBioDelivery Sciences Appoints Jeffrey A. Bailey to its Board of DirectorsGlobeNewswireRALEIGH, N.C., March 09, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...